NCT02143349

Brief Summary

Coleus forskohlii extract contains the bioactive compound, forskolin. Preliminary studies have shown that forskolin can increase fat metabolism thus reduce fat accumulation in both animals and humans. It has been suggested that forskolin may also suppress appetite thus reduce energy intake and results in weight loss. This study will evaluate the appetite suppressant properties of Coleus forskohlii extract. In addition the effect on central obesity and risk factors of metabolic syndrome will also be investigated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Apr 2014

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 21, 2014

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

May 21, 2014

Status Verified

May 1, 2014

Enrollment Period

1.1 years

First QC Date

May 17, 2014

Last Update Submit

May 17, 2014

Conditions

Keywords

obesityherbal remediesmetabolic disorders

Outcome Measures

Primary Outcomes (1)

  • changes in appetite will be assessed using visual analogue scale; blood hormone levels will also be measured using commercial kits.

    Baseline and 12 weeks

Secondary Outcomes (1)

  • reduction in central obesity - waist circumference will be measured on fortnight basis

    12 weeks

Other Outcomes (1)

  • alterations in blood lipids. This will be measured using commercial kits

    12 weeks

Study Arms (2)

Coleus forskohlii extract

EXPERIMENTAL

Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks

Dietary Supplement: Coleus forskohlii extract

Placebo

PLACEBO COMPARATOR

Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks

Other: Placebo

Interventions

Coleus forskohlii extractDIETARY_SUPPLEMENT

Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks

Coleus forskohlii extract
PlaceboOTHER

Ingestion of 250 mg placebo capsule twice a day for 12 weeks

Placebo

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Both Australian males and females, age 20-60 years, Overweight or obese (BMI \>25), waist circumference of \> 94 cm (male), waist circumference of \>80 cm (female)

You may not qualify if:

  • Cigarette smoker, hypertension, all types of heart, liver and kidney disease, pregnancy, lactating, Type 1 diabetes and weight loss medication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

College of Health and Biomedicine Victoria University

St Albans, Victoria, 14428, Australia

RECRUITING

Related Publications (2)

  • obesity

    BACKGROUND
  • Shivaprasad HN, Gopalakrishna S, Mariyanna B, Thekkoot M, Reddy R, Tippeswamy BS. Effect of Coleus forskohlii extract on cafeteria diet-induced obesity in rats. Pharmacognosy Res. 2014 Jan;6(1):42-5. doi: 10.4103/0974-8490.122916.

    PMID: 24497741BACKGROUND

Related Links

MeSH Terms

Conditions

Metabolic SyndromeObesityMetabolic Diseases

Condition Hierarchy (Ancestors)

Insulin ResistanceHyperinsulinismGlucose Metabolism DisordersNutritional and Metabolic DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2014

First Posted

May 21, 2014

Study Start

April 1, 2014

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

May 21, 2014

Record last verified: 2014-05

Locations